Inovio Free Cash Flow Yield vs Free Cash Flow Per Share Analysis

INO Stock

USD 4.07 0.01 0.25%

Inovio Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Inovio Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inovio Pharmaceuticals is a good investment. Please check the relationship between Inovio Pharmaceuticals Free Cash Flow Yield and its Free Cash Flow Per Share accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Free Cash Flow Yield vs Free Cash Flow Per Share

Free Cash Flow Yield vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inovio Pharmaceuticals Free Cash Flow Yield account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Inovio Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share is 0.43. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Inovio Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Inovio Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Inovio Pharmaceuticals are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Free Cash Flow Yield i.e., Inovio Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

0.43

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Most indicators from Inovio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 24th of November 2024, Sales General And Administrative To Revenue is likely to grow to 60.05, while Issuance Of Capital Stock is likely to drop about 9.8 M.

	2021	2022	2023	2024 (projected)
Interest Expense	1.9M	1.3M	1.2M	1.2M
Depreciation And Amortization	4.7M	5.5M	3.5M	2.4M

Interest Expense Depreciation And Amortization

Inovio Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Other Current Liab	Other Liab	Non Currrent Assets Other	Other Assets	Long Term Debt	Common Stock Total Equity
Total Assets		-0.34	0.71	0.97	0.77	-0.62	-0.53	0.59	0.79	0.67	1.0	0.75	-0.21	0.32	0.88	0.65	0.63	0.61	1.0	-0.36	0.66	-0.29	0.11	0.63	0.08	-0.32
Short Long Term Debt Total	-0.34		-0.26	-0.35	-0.2	0.1	0.57	-0.26	-0.21	0.35	-0.38	-0.13	0.68	0.0	-0.5	-0.59	-0.15	-0.5	-0.4	0.8	-0.4	0.81	-0.21	-0.17	0.11	-0.51
Total Current Liabilities	0.71	-0.26		0.59	0.66	-0.11	-0.67	0.81	0.26	0.39	0.69	0.59	-0.06	0.29	0.81	0.69	0.78	0.52	0.72	-0.33	0.84	-0.15	0.23	0.11	0.19	-0.38
Total Stockholder Equity	0.97	-0.35	0.59		0.63	-0.75	-0.43	0.48	0.83	0.62	0.97	0.74	-0.14	0.11	0.82	0.58	0.42	0.52	0.97	-0.31	0.53	-0.36	0.06	0.67	-0.08	-0.27
Property Plant And Equipment Net	0.77	-0.2	0.66	0.63		-0.14	-0.57	0.66	0.46	0.67	0.76	0.46	-0.17	0.7	0.62	0.61	0.85	0.77	0.75	-0.41	0.59	0.08	0.21	0.39	0.57	-0.3
Net Debt	-0.62	0.1	-0.11	-0.75	-0.14		-0.07	0.11	-0.9	-0.5	-0.61	-0.66	-0.05	0.21	-0.47	-0.08	0.07	0.05	-0.61	0.02	-0.19	0.21	0.07	-0.84	0.26	0.09
Retained Earnings	-0.53	0.57	-0.67	-0.43	-0.57	-0.07		-0.52	-0.16	-0.12	-0.54	-0.25	0.31	-0.3	-0.58	-0.98	-0.59	-0.85	-0.55	0.55	-0.64	0.44	-0.19	-0.09	-0.24	0.35
Accounts Payable	0.59	-0.26	0.81	0.48	0.66	0.11	-0.52		0.01	0.25	0.59	0.27	-0.06	0.27	0.67	0.55	0.65	0.6	0.6	-0.33	0.65	-0.11	0.18	-0.18	0.25	-0.2
Cash	0.79	-0.21	0.26	0.83	0.46	-0.9	-0.16	0.01		0.65	0.78	0.7	-0.22	0.22	0.62	0.31	0.3	0.23	0.77	-0.22	0.4	-0.24	0.01	0.95	0.02	-0.17
Non Current Assets Total	0.67	0.35	0.39	0.62	0.67	-0.5	-0.12	0.25	0.65		0.62	0.69	0.27	0.44	0.39	0.23	0.52	0.31	0.61	0.18	0.26	0.37	0.07	0.62	0.31	-0.62
Cash And Short Term Investments	1.0	-0.38	0.69	0.97	0.76	-0.61	-0.54	0.59	0.78	0.62		0.71	-0.24	0.3	0.87	0.67	0.6	0.63	1.0	-0.41	0.64	-0.34	0.1	0.61	0.06	-0.29
Net Receivables	0.75	-0.13	0.59	0.74	0.46	-0.66	-0.25	0.27	0.7	0.69	0.71		0.09	0.1	0.63	0.37	0.41	0.21	0.73	-0.08	0.42	-0.08	0.15	0.65	-0.08	-0.25
Common Stock Shares Outstanding	-0.21	0.68	-0.06	-0.14	-0.17	-0.05	0.31	-0.06	-0.22	0.27	-0.24	0.09		-0.43	-0.4	-0.31	-0.32	-0.3	-0.25	0.49	-0.37	0.72	-0.19	-0.21	0.0	-0.38
Non Current Liabilities Total	0.32	0.0	0.29	0.11	0.7	0.21	-0.3	0.27	0.22	0.44	0.3	0.1	-0.43		0.27	0.27	0.83	0.44	0.29	-0.28	0.4	0.2	0.13	0.23	0.67	-0.19
Other Current Assets	0.88	-0.5	0.81	0.82	0.62	-0.47	-0.58	0.67	0.62	0.39	0.87	0.63	-0.4	0.27		0.67	0.65	0.48	0.89	-0.42	0.87	-0.5	0.14	0.47	0.03	-0.17
Other Stockholder Equity	0.65	-0.59	0.69	0.58	0.61	-0.08	-0.98	0.55	0.31	0.23	0.67	0.37	-0.31	0.27	0.67		0.58	0.87	0.67	-0.56	0.65	-0.48	0.18	0.21	0.19	-0.36
Total Liab	0.63	-0.15	0.78	0.42	0.85	0.07	-0.59	0.65	0.3	0.52	0.6	0.41	-0.32	0.83	0.65	0.58		0.6	0.61	-0.38	0.76	0.04	0.22	0.21	0.55	-0.34
Property Plant And Equipment Gross	0.61	-0.5	0.52	0.52	0.77	0.05	-0.85	0.6	0.23	0.31	0.63	0.21	-0.3	0.44	0.48	0.87	0.6		0.62	-0.54	0.43	-0.28	0.22	0.15	0.35	-0.28
Total Current Assets	1.0	-0.4	0.72	0.97	0.75	-0.61	-0.55	0.6	0.77	0.61	1.0	0.73	-0.25	0.29	0.89	0.67	0.61	0.62		-0.41	0.67	-0.35	0.11	0.61	0.05	-0.28
Intangible Assets	-0.36	0.8	-0.33	-0.31	-0.41	0.02	0.55	-0.33	-0.22	0.18	-0.41	-0.08	0.49	-0.28	-0.42	-0.56	-0.38	-0.54	-0.41		-0.44	0.41	-0.04	-0.13	-0.22	-0.41
Other Current Liab	0.66	-0.4	0.84	0.53	0.59	-0.19	-0.64	0.65	0.4	0.26	0.64	0.42	-0.37	0.4	0.87	0.65	0.76	0.43	0.67	-0.44		-0.34	0.21	0.29	0.34	-0.23
Other Liab	-0.29	0.81	-0.15	-0.36	0.08	0.21	0.44	-0.11	-0.24	0.37	-0.34	-0.08	0.72	0.2	-0.5	-0.48	0.04	-0.28	-0.35	0.41	-0.34		-0.14	-0.19	0.37	-0.28
Non Currrent Assets Other	0.11	-0.21	0.23	0.06	0.21	0.07	-0.19	0.18	0.01	0.07	0.1	0.15	-0.19	0.13	0.14	0.18	0.22	0.22	0.11	-0.04	0.21	-0.14		0.07	0.16	0.07
Other Assets	0.63	-0.17	0.11	0.67	0.39	-0.84	-0.09	-0.18	0.95	0.62	0.61	0.65	-0.21	0.23	0.47	0.21	0.21	0.15	0.61	-0.13	0.29	-0.19	0.07		0.08	-0.1
Long Term Debt	0.08	0.11	0.19	-0.08	0.57	0.26	-0.24	0.25	0.02	0.31	0.06	-0.08	0.0	0.67	0.03	0.19	0.55	0.35	0.05	-0.22	0.34	0.37	0.16	0.08		-0.16
Common Stock Total Equity	-0.32	-0.51	-0.38	-0.27	-0.3	0.09	0.35	-0.2	-0.17	-0.62	-0.29	-0.25	-0.38	-0.19	-0.17	-0.36	-0.34	-0.28	-0.28	-0.41	-0.23	-0.28	0.07	-0.1	-0.16

Click cells to compare fundamentals

Inovio Pharmaceuticals Account Relationship Matchups

Inovio Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	144.0M	539.8M	495.9M	348.5M	172.9M	131.2M
Total Current Liabilities	32.0M	41.7M	65.7M	96.9M	42.6M	23.4M
Total Stockholder Equity	3.4M	461.1M	399.7M	222.4M	117.3M	95.2M
Property Plant And Equipment Net	26.6M	24.1M	29.0M	18.0M	14.5M	7.5M
Net Debt	77.3M	(211.7M)	(38.1M)	(14.3M)	15.9M	16.7M
Retained Earnings	(739.8M)	(906.2M)	(1.2B)	(1.5B)	(1.6B)	(1.5B)
Accounts Payable	7.6M	1.5M	28.0M	21.1M	4.6M	5.0M
Cash	22.2M	250.7M	71.1M	46.3M	14.3M	13.6M
Non Current Assets Total	49.8M	68.6M	47.5M	33.3M	19.8M	28.2M
Cash And Short Term Investments	89.5M	411.6M	401.3M	253.0M	145.3M	92.0M
Net Receivables	2.0M	19.1M	8.0M	11.7M	2.4M	3.9M
Common Stock Shares Outstanding	8.2M	12.9M	17.4M	19.9M	22.2M	28.0M
Liabilities And Stockholders Equity	144.0M	539.8M	495.9M	348.5M	172.9M	131.2M
Non Current Liabilities Total	106.6M	36.9M	30.5M	29.3M	13.0M	12.1M
Other Current Assets	2.6M	40.5M	39.1M	50.5M	5.4M	6.9M
Other Stockholder Equity	742.6M	1.4B	1.6B	1.7B	1.7B	1.8B
Total Liab	138.5M	78.6M	96.3M	126.2M	55.6M	35.5M
Property Plant And Equipment Gross	26.6M	24.1M	48.0M	18.0M	35.3M	37.1M
Total Current Assets	94.2M	471.2M	448.4M	315.2M	153.1M	103.0M
Accumulated Other Comprehensive Income	472.6K	(256.2K)	(282.2K)	(698.7K)	(662.6K)	(629.5K)
Intangible Assets	3.7M	3.1M	2.6M	2.1M	2.4M	2.3M
Other Current Liab	22.1M	37.9M	35.1M	73.0M	18.7M	11.5M
Other Liab	9.1M	206.4K	111.2K	32.0K	36.9K	35.0K
Non Currrent Assets Other	(5.4M)	22.2M	(1.5M)	(1.6M)	605.3K	635.6K
Other Assets	2.7M	43.6M	1.4M	684.0K	1.0	0.95
Common Stock Total Equity	101.4K	186.9K	217.4K	253.1K	227.8K	216.4K
Common Stock	101.4K	186.9K	217.4K	253.1K	22.8K	21.7K
Property Plant Equipment	12.8M	11.3M	17.5M	7.7M	8.9M	5.2M
Current Deferred Revenue	257.2K	124.1K	46.6K	21.6K	24.9K	23.6K
Short Term Investments	67.3M	160.9M	330.2M	206.7M	131.0M	85.0M
Net Tangible Assets	(10.8M)	447.5M	386.5M	209.7M	241.2M	159.6M
Retained Earnings Total Equity	(739.8M)	(906.2M)	(1.2B)	(1.5B)	(1.3B)	(1.3B)
Capital Surpluse	742.6M	1.4B	1.6B	1.7B	2.0B	2.1B

When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:

How To Invest In Inovio

Details

Is Inovio Stock a good investment?

Details

What is Inovio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.43)

Revenue Per Share

0.025

Quarterly Revenue Growth

(0.55)

Return On Assets

(0.40)

Return On Equity

(0.91)

The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inovio Free Cash Flow Yield vs Free Cash Flow Per Share Analysis

Free Cash Flow Yield vs Free Cash Flow Per Share

Free Cash Flow Yield vs Free Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Free Cash Flow Per Share

Inovio Pharmaceuticals fundamental ratios Correlations

Inovio Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inovio Pharmaceuticals fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets
Cash And Short Term Investments	+ 0.97	Total Stockholder Equity
Total Current Assets	+ 0.97	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.9	Net Debt
Property Plant And Equipment Gross	- 0.85	Retained Earnings
Other Assets	- 0.84	Net Debt
Net Debt	- 0.75	Total Stockholder Equity
Retained Earnings	- 0.67	Total Current Liabilities